2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 291-292
Technology and Procedures, Omics Technologies, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

21 Decitabine restrains hyperinflammation through P21-mediated cell cycle arrest in hemophagocytic lymphohistiocytosis

Xinyue Deng, MD, Bo Zhang2, Heng Mei3, Tao Guo4, Zhiqing Pang5, Hu Yu, MD6
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
5 School of Pharmacy, Fudan University, Shanghai, China
6 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. Current HLH therapies largely rely on chemotherapy, which is often limited by significant toxicity. In our previous unpublished study, Decitabine (DAC), a DNA methyltransferase inhibitor, markedly alleviated systemic inflammation and improved HLH manifestations in mouse models with limited toxicity. Unexpectedly, integrative methylome and transcriptome analyses revealed a paradoxical pattern: DAC activated inflammatory signaling pathways while broadly suppressing cellular metabolism, biosynthesis, secretion, and energy production, suggesting an anti-inflammatory mechanism independent of direct pathway inhibition. In the present study, we investigated the mechanism by which DAC restrains systemic inflammation, identified P21-mediated cell cycle regulation as a key mechanism, and explored the therapeutic potential of P21-based strategies for HLH and other systemic inflammatory disorders.

METHODS: To investigate the effects of DAC on highly activated inflammatory cells, RAW264.7 macrophages activated by various inflammatory stimuli, NF-κB/ISRE dual-reporter THP-1 cells, and CpG-induced HLH mice were treated with graded doses of DAC. Inflammatory signaling, cell proliferation, cell cycle progression, apoptosis, global protein synthesis, and DNA methylation were subsequently evaluated using bulk RNA-seq, signaling reporter assays, flow cytometry, immunoblotting, immunofluorescence, SUnSET assays, and whole-genome bisulfite sequencing (WGBS). The regulatory effects of DAC on the cell cycle were further investigated. The expression, subcellular localization, and functional role of cell cycle regulators, particularly P21, were examined. To determine the role of P21 in the DAC-mediated anti-inflammatory effects, a P21-deficient RAW264.7 cell line was then generated using CRISPR/Cas9. In parallel, the P21-selective inhibitor UC2288 was administered with DAC in vitro and in HLH mice. Finally, the mechanisms underlying DAC-induced P21 accumulation were preliminarily investigated by integrating analyses of protein synthesis and degradation.

RESULTS: DAC showed a consistent dose-dependent response in activated RAW264.7 macrophages and the CpG-induced HLH mice. Inflammatory indicators, including pSTAT1, CD80 expression, and cytokine production, exhibited a biphasic response to graded DAC dosing. In contrast, the proportions of G2/M-phase cells and apoptotic cells increased, accompanied by graded decreases in total cell number and EdU-positive proliferating cells. RNA sequencing, WGBS, and NF-κB/ISRE reporter assays further demonstrated that DAC enhanced rather than suppressed canonical inflammatory pathways. These findings suggested that DAC restrained inflammatory output by limiting the expansion of inflammatory cells through G2/M cell cycle arrest despite transcriptional activation of inflammatory pathways. Marked accumulation of P21 was consistently observed in DAC-treated RAW264.7 cells and splenic macrophages from CpG-HLH mice, indicating that P21-mediated cell cycle arrest might represent a key mechanism. P21 knockout significantly attenuated DAC-induced G2/M arrest, proliferation inhibition, and apoptosis in RAW264.7 cells. Similarly, the selective P21 inhibitor UC2288 partially reversed DAC-induced G2/M arrest, early apoptosis, and systemic anti-inflammatory effects in vitro and in HLH mice. Finally, Ribosome profiling, SUnSET assays, and CHX chase assays suggested that DAC-induced P21 accumulation was primarily associated with impaired protein degradation rather than transcriptional or translational upregulation.

CONCLUSIONS: This study identifies P21-mediated cell cycle arrest as a key mechanism underlying the anti-inflammatory effects of DAC in HLH. Pharmacological induction of P21 by agents such as DAC and P21-activating small RNAs may provide a feasible strategy for suppressing cytokine storms with reduced toxicity in HLH patients. Furthermore, developing small-molecule agents targeting P21 in activated inflammatory cells may expand our understanding of how cell cycle regulation shapes inflammatory responses and provide new therapeutic approaches for HLH and other hyperinflammatory disorders, including chimeric antigen receptor T-cell (CAR-T)-associated cytokine release syndrome.

Xinyue Deng, MD: No relevant conflicts of interest to declare.